Cancer Research UK Discovery Programme Award 2026

Cancer Research UK Discovery Programme Award 2026

Due Date: 09/29/2026

The Cancer Research UK Discovery Programme Award 2026 provides long-term support for established researchers pursuing ambitious and creative programmes addressing fundamental questions in cancer biology and early-stage translational research.

Awards provide up to £2.5 million over five years and may support multidisciplinary teams investigating cancer from molecular and cellular mechanisms through whole-body biology, including novel technologies, imaging, radiotherapy approaches, disease-specific biology, and preclinical research underpinning future therapeutic development. The next outline application deadline is September 29, 2026. (Cancer Research UK)

Eligibility Criteria

  • Applicants may be scientists, clinicians, or healthcare workers.
  • The lead applicant must be based at a UK university, medical school, hospital, or research institution.
  • Applicants must hold a post that is fully funded throughout the award period by the relevant Higher Education Funding Council, NHS, or equivalent.
  • Previous Cancer Research UK funding is not required.
  • Commercial organisations may also participate as collaborators, subject to CRUK funding conditions.
  • Researchers receiving core funding from a CRUK institute may not normally apply as lead applicants, but may participate as co-investigators or collaborators.
  • Applicants must contact CRUK for an informal and confidential discussion before applying.

Funding Details

  • Maximum funding: £2.5 million.
  • Duration: Up to 5 years.
  • Funding may support postdoctoral researchers.

Deadline

  • Current outline round opened: April 1, 2026.
  • Outline application deadline: September 29, 2026.
  • Committee shortlisting: November 2026.
  • Invited full application deadline: January 2027.
  • Expert Review Panel interviews: March–April 2027.
  • Final committee review: June 2027.

Further Information

  • CRUK encourages collaborative and multidisciplinary research programmes.
  • Clinical trials and translational research immediately linked to a clinical trial are not suitable for this scheme.
  • Assessment considers scientific excellence, innovation, cancer relevance, and alignment with CRUK’s research strategy.
  • Official program page: View the official website
  • Contact: discovery@cancer.org.uk.